Brain Tumor Cell Targeting Technology
Arch Biopartners Inc. announced today that data relating to proprietary technology identifying brain tumor targeting peptides developed by Dr. Stephen Robbins, Dr. Donna Senger and Dr. Jennifer Rahn and their colleagues at the University of Calgary will be presented on Nov 24, 2013 at the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology being held in conjunction with the 18th Annual Meeting of the Society for Neuro-Oncology taking place in San Francisco, November 21-24.
The presentation will describe how Dr. Robbins and his colleagues used a panel of peptides to successfully image a range of diffuse infiltrating brain tumours that are notoriously difficult to image using standard MRI. Additionally, they identified peptides that possess the ability to inhibit cell invasion, or target subsets of tumour cells that had 'stem-like' properties. Thus, in addition to imaging, these peptides may be useful as therapeutics, as delivery agents for chemotherapeutics, or as diagnostic indicators.